Results 171 to 180 of about 10,484 (237)
JAMA: The Journal of the American Medical Association, 1985 To the Editor.— In a recent article Garewal et al1demonstrated that danazol, an attenuated androgen, given at a dose of 600 mg daily for eight to 14 weeks, is not useful in the treatment of factor VIII—deficient and factor IX—deficient hemophilic patients.
Ambriz R, J Pizzuto, Cecilia Guillen
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Annals of Internal Medicine, 1982
Danazol, approved 5 years ago for the treatment of pelvic endometriosis, has recently been approved for treating cystic disease of the breast. As the mechanisms of action of this drug are made clear, the clinical syndromes that can be treated by this impeded androgen have increased dramatically. Results of controlled prospective clinical studies on the
A E, Madanes, M, Farber
openaire +4 more sources
Danazol, approved 5 years ago for the treatment of pelvic endometriosis, has recently been approved for treating cystic disease of the breast. As the mechanisms of action of this drug are made clear, the clinical syndromes that can be treated by this impeded androgen have increased dramatically. Results of controlled prospective clinical studies on the
A E, Madanes, M, Farber
openaire +4 more sources
2022
A comprehensive profile of danazol describing the nomenclatures, formulae, elemental composition, appearance, uses and applications is presented. The profile contains the method which was utilized for the preparation of the drug substance and its respective scheme is outlined.
openaire +2 more sources
A comprehensive profile of danazol describing the nomenclatures, formulae, elemental composition, appearance, uses and applications is presented. The profile contains the method which was utilized for the preparation of the drug substance and its respective scheme is outlined.
openaire +2 more sources
Danazol for Lupus Thrombocytopenia
Archives of Internal Medicine, 1985Danazol therapy was used in the treatment of three consecutive patients with lupus-associated thrombocytopenia refractory to high-dose prednisone therapy (two patients) or in whom high-dose prednisone therapy was considered contraindicated (one patient). Treatment was associated in each case with an increase in platelet count but was complicated in two
P. Cook, Catherine T. Marino
openaire +3 more sources
Annals of Internal Medicine, 1979
Excerpt To the editor: Dr. Spaulding has reported in the May 1979 issue (1) a patient with hereditary angioedema who developed a rise in the level of creatine phosphokinase during treatment with da...
Jack Hirschowitz +2 more
openaire +3 more sources
Excerpt To the editor: Dr. Spaulding has reported in the May 1979 issue (1) a patient with hereditary angioedema who developed a rise in the level of creatine phosphokinase during treatment with da...
Jack Hirschowitz +2 more
openaire +3 more sources
JAMA: The Journal of the American Medical Association, 1985
Danazol is a 2,3-isoxazol derivative of 17 α-ethinyl testosterone; it is known to be an anabolic steroid with mild androgenic activity. The administration of the drug is associated with raised plasma levels of several proteins including prealbumin, haptoglobulin, transferrin, antithrombin III, prothrombin, plasminogen, α1-antitrypsin, and Cl esterase ...
openaire +3 more sources
Danazol is a 2,3-isoxazol derivative of 17 α-ethinyl testosterone; it is known to be an anabolic steroid with mild androgenic activity. The administration of the drug is associated with raised plasma levels of several proteins including prealbumin, haptoglobulin, transferrin, antithrombin III, prothrombin, plasminogen, α1-antitrypsin, and Cl esterase ...
openaire +3 more sources
Danazol Therapy in Myelodysplasia
Annals of Internal Medicine, 1985Platelet-associated IgG was markedly elevated in three patients with myelodysplasia and severe thrombocytopenia that had become refractory to platelet transfusions. The patients were treated with danazol because of its efficacy in treating immune thrombocytopenic purpura where platelet destruction is primarily mediated by IgG autoantibodies.
Douglas B. Cines +2 more
openaire +3 more sources